Progression of myelodysplasia patient 1
| Time from Primary Diagnosis . | Karyotype . | FISH Results . | Clinical Status . | TP53 Status . |
|---|---|---|---|---|
| 0 mo | 46, XX, t(15;17)(q22;q21) | APL t(15;17) | Presentation | Normal |
| 6 mo | 46, XX | Complete Remission | Normal | |
| 21 mo | ND | 13% der(5;17) | Complete Remission | Normal |
| 24 mo | ND | 33% der(5;17) | Complete Remission | Normal |
| 29 mo | 45, XX, −5, add(17)(p11.2)[6] | 43% der(5;17) | Complete Remission | Normal |
| 32 mo | 45, XX, −5, add(17)(p11.2)[19] | 74% der(5;17) | Complete Remission | Normal/Mutant |
| 35 mo | 45, XX, −5, add(17)(p11.2)[5] 42-45, XX, chromosomes exhibiting shared abnormalities consisting of −3, −5, add(6)(p25), −7, −14, −15, add(17)(p11.2), +2mar[15] | 95% der(5;17) | Relapse MDS 9% blasts | Mutant |
| Time from Primary Diagnosis . | Karyotype . | FISH Results . | Clinical Status . | TP53 Status . |
|---|---|---|---|---|
| 0 mo | 46, XX, t(15;17)(q22;q21) | APL t(15;17) | Presentation | Normal |
| 6 mo | 46, XX | Complete Remission | Normal | |
| 21 mo | ND | 13% der(5;17) | Complete Remission | Normal |
| 24 mo | ND | 33% der(5;17) | Complete Remission | Normal |
| 29 mo | 45, XX, −5, add(17)(p11.2)[6] | 43% der(5;17) | Complete Remission | Normal |
| 32 mo | 45, XX, −5, add(17)(p11.2)[19] | 74% der(5;17) | Complete Remission | Normal/Mutant |
| 35 mo | 45, XX, −5, add(17)(p11.2)[5] 42-45, XX, chromosomes exhibiting shared abnormalities consisting of −3, −5, add(6)(p25), −7, −14, −15, add(17)(p11.2), +2mar[15] | 95% der(5;17) | Relapse MDS 9% blasts | Mutant |
ND = not done; APL = acute promyelocytic leukemia; MDS = myelodysplasia.